Auditor's Report and
Audited Financial Statements
of
The IBN SINA Pharmaceutical Industry PLC.
For the year ended 30 June 2026

CHARTERED ACCOUNTANTS
Since 1965

MALEK SIDDIQUI WALI
CHARTERED ACCOUNTANTS

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-bd.com

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of THE IBN SINA Pharmaceutical Industry PLC.

Report on the Audit of the Consolidated and Separate Financial Statements

Opinion

We have audited the consolidated financial statements of THE IBN SINA Pharmaceutical Industry PLC. and its subsidiaries (the "Group") as well as the separate financial statements of THE IBN SINA Pharmaceutical Industry PLC. (the "Company"), which comprise the consolidated and separate statements of financial position as at June 30, 2026, the consolidated and separate statements of profit or loss and other comprehensive income, consolidated and separate statements of changes in equity and consolidated and separate statements of cash flows for the year then ended, and notes to the consolidated and separate financial statements, including material accounting policy information and other explanatory information.

In our opinion, the accompanying consolidated and separate financial statements give a true and fair view of the consolidated financial position of the Group and the separate financial position of the Company as at June 30, 2026, and of their consolidated and separate financial performance and consolidated and separate cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the Financial Reporting Council (FRC) of Bangladesh.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated and Separate Financial Statements section of our report. We are independent of the Group and the Company in accordance with the ethical requirements of the Financial Reporting Council together with the ethical requirements of the Institute of Chartered Accountants of Bangladesh (ICAB) Bye-Laws that are relevant to audits of the financial statements of public interest entities in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated and separate financial statements of the current period. These matters were addressed in the context of our audit of the consolidated and separate financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Risk	Our response
Revenue recognition	
At the year ended, the company's reported total revenue of Tk. 13,899,792,434. Revenue is measured net of trade discount and VAT. Time of revenue recognition is matter. The revenue may overstated for the early recognition of revenue to achieve the desire result.	We have tested the design and operating effectiveness of key controls focusing on the following: • Policy of revenue recognition: • Issuance of VAT challan; • Segregation of duties in invoice creation and modification; and • Timing of revenue recognition. Our substantive procedures in relation to the revenue recognition comprises the following: • Obtaining supporting documentation for sales transactions recorded either side of year end as well as credit notes issued after the year end date to determine whether revenue was recognized in the correct period; • VAT is correctly dealt with;

Risk	Our response
	• Critically assessing manual journals posted to revenue to identify unusual or irregular items; and • Finally assessed the appropriateness and presentation of disclosures against relevant accounting Standards.
Please see the note 24.A in this financial statements.	
Valuation of inventory	
The balance of inventory of the Company at the year-end was Tk. 1,972,382,955 held in the company's warehouse. Inventories should carried at the lower of cost and net realizable value. As a result, the managements apply judgment in determining the appropriate values of inventory.	We challenged the appropriateness of management's assumptions applied in calculating the value of the inventory and related provisions by: • evaluating the design and implementation of key inventory controls operating across the Company in respect of inventory management; • to attend the physical inventory counts and reconciling the count results to the inventory listings to test the completeness of data; • to review the inventory costing procedures and methodology. • comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories and comparison to the associated provision to assess whether inventory provisions are complete; • reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year; and • Challenging the completeness of inventory provisions through assessing actual and forecast sales of inventory lines to assess whether provisions for slow- moving/obsolete stock are valid and complete.
Please see the note 8 B in this financial statements.	
Measurement and recognition of deferred tax	
The balance of reported deferred tax liability of the company was Tk. 93,028,338 as on June 30, 2026. The risk for the financial statements is that these provisions may not properly measured for all types of temporary difference as per IAs 12: Income Tax.	We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax. We have assessed the appropriateness of the carrying amounts of net asset value as per tax base and accounting base. We have also assessed the rate of deferred for each temporary difference. Also, we examined the accounting treatment of deferred tax.
Please see the note 19 in this financial statements.	

Other Matter:

The statutory auditor of the company for the year ended June 30, 2025 (comparative financial statements for 2025) was S. F. Ahmed & Co., Chartered Accountants, who issued an unmodified audit opinion on the financial statements. As S. F. Ahmed & Co., Chartered Accountants also audited the preceding financial year, we have not expressed a separate opinion on the opening balances of the current year's financial statements.

Other Information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Consolidated and Separate Financial Statements

Management is responsible for the preparation of the consolidated and separate financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the IASB and adopted by FRC, and for such internal control as management determines is necessary to enable the preparation of consolidated and separate financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated and separate financial statements, management is responsible for assessing the Group's and the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's and the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated and Separate Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated and separate financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated and separate financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated and separate financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's or the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated and separate financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based

on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group or the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated and separate financial statements, including the disclosures, and whether the consolidated and separate financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the consolidated financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated and separate financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and Financial Reporting Act 2015, we also report the following:

a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) in our opinion, proper books of account as required by law have been kept by the Group and the Company so far as it appeared from our examination of these books;

c) the consolidated and separate statements of financial position and the consolidated and separate statements of comprehensive income dealt with by the report are in agreement with the books of account and returns; and

d) the consolidated and separate financial statements have been prepared in accordance with standards, framework, compliance and guidelines adopted and promulgated by the Financial Reporting Council.

Md. Waliullah, FCA, Enrolment No: 0247
Malek Siddiqui Wali, Chartered Accountants
FRC Firm Enlistment No.: CAF - 001 –091
RJSC Firm Registration No: P-50041/2022
Dhaka/ September 30, 2026
DVC: 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 June 2026

Amount in Taka

	Notes	30 June 2026	30 June 2025
ASSETS:			
Non-Current Assets		**7,507,719,201**	**4,701,323,681**
Property, Plant and Equipment	04.A	2,638,512,168	2,655,519,636
Capital Work-In-Progress	05.A	4,785,835,577	1,932,358,746
Right-of-Use Assets	05.B	8,268,178	33,072,711
Advances, Deposits & Prepayments	10.A.1	33,965,070	33,715,070
Financial Assets	06.A	41,138,209	46,657,518
Current Assets		**3,302,659,427**	**2,845,250,397**
Financial assets	08.A	22,500,000	22,500,000
Inventories	08.B	1,972,382,955	1,808,087,123
Trade and Other Receivables	09.A	189,774,389	196,052,607
Advances, Deposits & Prepayments	10.A.1	820,696,923	503,707,520
Cash & Cash Equivalents	11.A	297,305,160	314,903,147
TOTAL ASSETS		**10,810,378,628**	**7,546,574,078**
SHAREHOLDERS' EQUITY AND LIABILITIES:			
EQUITY:		**4,655,848,970**	**3,997,848,260**
Equity Attributable to the Owners of the Company		4,516,608,247	3,926,901,664
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
Fair Value Reserve	14	(20,511,709)	(15,544,331)
Retained Earnings	15.A	4,220,291,576	3,625,617,615
Non Controlling Interest	15.B	139,240,723	70,946,596
LIABILITIES:			
Non-Current Liabilities		**1,290,768,614**	**1,072,158,461**
Long Term Finance	16.A	1,197,232,556	974,705,376
Employee Benefit Obligations	17.A	507,721	990,546
Deferred Tax Liabilities	19	93,028,338	96,462,538
Current Liabilities		**4,863,761,044**	**2,476,567,357**
Short Term Finance	20.A	2,636,364,359	953,683,239
Current Portion of Long Term Finance	21	172,534,991	119,445,855
Lease Liabilities	17.B	-	23,798,698
Trade and Other Payables	22.A	1,307,039,568	842,289,127
Unclaimed Dividend	22.A.1	28,040,490	42,104,508
Provision for Corporate Tax	23.A	719,781,636	495,245,930
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**10,810,378,628**	**7,546,574,078**
Net Assets Value (NAV) Per Share	33.01.B	**144.56**	**125.69**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026

Document verification code(DVC) No : 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the year ended 30 June 2026

	Notes	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
REVENUE	24.A	13,899,792,434	11,883,593,713
Cost of goods sold	25.A	(8,147,083,860)	(7,083,739,867)
GROSS PROFIT		**5,752,708,574**	**4,799,853,846**
OPERATING EXPENSES		**(4,592,541,950)**	**(3,854,323,797)**
Administrative expenses	27.01	(318,137,538)	(267,068,903)
Selling & distribution expenses	28.01	(4,274,404,411)	(3,587,254,894)
OPERATING PROFIT		**1,160,166,625**	**945,530,049**
Financial charges	33.04	(127,838,224)	(87,403,328)
Other income	29.01	35,232,241	25,206,023
Profit before WPPF and Welfare Fund		**1,067,560,642**	**883,332,743**
Workers' P.P. fund & welfare fund	30.01	(52,979,904)	(43,358,391)
PROFIT BEFORE TAX		**1,014,580,738**	**839,974,353**
Income tax expenses:	31.02	(221,653,436)	(206,718,125)
NET PROFIT AFTER TAX		**792,927,301**	**633,256,228**
Profit/(Loss) Attributable to:			
Owner of the Company		**794,633,174**	**633,189,350**
Non-controlling interest	33.05	(1,705,873)	66,877
		792,927,301	**633,256,228**
Other Comprehensive Income:			
Change in fair value of marketable securities	32	(5,519,309)	(7,704,012)
Deferred tax		551,931	770,401
Total other comprehensive income for the year (net of tax)		(4,967,378)	(6,933,611)
Total Comprehensive Income for the year		**787,959,923**	**626,322,617**
Total Comprehensive income Attributable to:			
Owner of the Company		789,665,796	626,255,739
Non-controlling interest	33.05	(1,705,873)	66,877
		787,959,923	**626,322,617**
Earnings Per Share (EPS)	33.01.A	**25.43**	**20.27**
Number of Shares used to Compute EPS		**31,243,627**	**31,243,627**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June 2026

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Fair Value Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2024	**312,436,270**	**4,392,110**	**(8,610,721)**	**3,189,263,114**	**35,879,718**	**3,533,360,493**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2025	-	-	(6,933,611)	633,189,350	66,877	626,322,617
Dividend for the year 30 June 2024 (Cash-63%)				(196,834,850)		(196,834,850)
Issued during the year					35,000,000	35,000,000
Balance as at 30 June 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,625,617,615**	**70,946,596**	**3,997,848,260**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2026			(4,967,378)	794,633,174	(1,705,873)	787,959,923
Dividend for the year 30 June 2025 (Cash-64%)				(199,959,213)		(199,959,213)
Issued during the year					70,000,000	70,000,000
Balance as at 30 June 2026	**312,436,270**	**4,392,110**	**(20,511,710)**	**4,220,291,576**	**139,240,723**	**4,655,848,970**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CASH FLOWS
For the year ended 30 June 2026

	Amount in Taka	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
Cash Flows From Operating Activities		
Received from revenue and others	13,915,712,595	11,898,203,387
Payment for operation, expenses & others	(12,406,765,776)	(10,913,617,736)
Miscellaneous income	10,501,552	3,470,820
Cash generated from operations	**1,519,448,370**	**988,056,471**
Cash payment for income tax paid	(205,988,714)	(180,666,966)
Payment for financial charges	(127,838,224)	(83,710,869)
Net cash generated from operating activities	**1,185,621,432**	**723,678,635**
Cash Flows From Investing Activities		
Acquisition of property, plant and equipment	(3,033,192,371)	(976,264,540)
Proceeds from sales of motor vehicles	-	(5,232,246)
Profit received from MTDR	(1,574,907)	-
Acquisition of financial assets	-	142,986,813
Profit from MTDR	2,599,404	-
Dividend received/ IBBL-MPB	507,239	1,972,684
Bank profit received	5,132,598	7,696,969
Net cash used in investing activities	**(3,026,528,036)**	**(828,840,320)**
Cash Flows From Financing Activities		
Payment of dividend	(214,023,231)	(193,870,939)
Long term finance received/(paid) from bank (Net)	222,527,180	444,214,854
Transactions Non Controlling Interest	70,000,000	35,000,000
Short term finance received/(paid) from bank (Net)	1,735,770,256	(231,726,594)
Net cash used in financing activities	**1,814,274,204**	**53,617,321**
Increase/(decrease) in cash and cash equivalents	(26,632,400)	(51,544,364)
Cash and cash equivalents at the opening	314,903,148	365,229,893
Foreign exchange fluctuation gain/(loss) on FCAD ERQ Accounts	9,034,412	1,217,618
Cash and cash equivalents at the closing	**297,305,160**	**314,903,147**
NOCFPS (Note 33.02.01)	**37.95**	**23.16**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF FINANCIAL POSITION
As at 30 June 2026

Amount in Taka

	Notes	30 June 2026	30 June 2025
ASSETS			
Non-Current Assets		**7,461,742,876**	**4,710,090,479**
Property, Plant and Equipment	04	2,389,616,834	2,431,653,536
Capital Work-In-Progress	05	3,779,835,116	1,155,822,174
Right of Use Assets	05.B	8,268,178	33,072,711
Financial Assets	06	12,138,209	17,657,518
Advances, Deposits & Prepayments	10.1	33,715,070	33,715,070
Investment in Subsidiary	07	1,238,169,470	1,038,169,470
Current Assets		**2,851,217,065**	**2,424,153,681**
Financial assets	08	22,500,000	22,500,000
Inventories	08.1	1,738,794,887	1,603,775,310
Trade and Other Receivables	09	180,245,053	187,596,187
Advances, Deposits & Prepayments	10.1	749,291,153	429,600,396
Cash & Cash Equivalents	11	160,385,971	180,681,788
TOTAL ASSETS		**10,312,959,941**	**7,134,244,160**
SHAREHOLDERS' EQUITY AND LIABILITIES			
EQUITY:		**4,520,143,263**	**3,932,383,056**
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
Fair Value Reserve	14	(20,511,709)	(15,544,331)
Retained Earnings	15	4,223,826,592	3,631,099,007
LIABILITIES			
Non-Current Liabilities		**1,081,580,746**	**848,925,369**
Long Term Finance	16	990,125,690	753,223,072
Employee Benefit Obligations	17	507,721	990,546
Deferred Tax Liabilities	18	90,947,336	94,711,750
Current Liabilities		**4,711,235,932**	**2,352,935,735**
Short Term Finance	20	2,607,058,173	933,771,898
Current Portion of Long Term Finance	21	172,534,991	119,445,855
Lease Liabilities	17.B	-	23,798,698
Trade and Other Payables	22	1,238,363,259	775,229,847
Unclaimed Dividend	22.A.1	28,040,490	42,104,508
Provision for Corporate Tax	23	665,239,020	458,584,929
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**10,312,959,941**	**7,134,244,160**
Net Assets Value (NAV) Per Share	33.01	**144.67**	**125.86**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the year ended 30 June 2026

Amount in Taka

	Notes	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
REVENUE	24	12,418,880,056	10,725,957,022
Cost of goods sold	25	(7,331,664,071)	(6,429,003,064)
GROSS PROFIT		**5,087,215,985**	**4,296,953,958**
OPERATING EXPENSES		**(3,948,680,634)**	**(3,329,259,450)**
Administrative expenses	27	(253,832,840)	(225,676,621)
Selling & Distribution expenses	28	(3,694,847,793)	(3,103,582,828)
OPERATING PROFIT		**1,138,535,351**	**967,694,508**
Financial charges	33.04	(127,838,224)	(87,403,328)
Other income	29	35,237,698	21,739,663
Profit before WPPF and Welfare Fund		**1,045,934,826**	**902,030,843**
Workers' P.P. fund & welfare fund	30	(49,806,420)	(42,953,850)
PROFIT BEFORE TAX		**996,128,405**	**859,076,993**
Income tax expenses	31	(203,441,607)	(198,914,969)
NET PROFIT AFTER TAX		**792,686,798**	**660,162,024**
Other Comprehensive Income			
Change in fair value of marketable securities	32	(5,519,309)	(7,704,012)
Deferred tax		551,931	770,401
Total other comprehensive income for the year (net of tax)		(4,967,378)	(6,933,611)
Total Comprehensive Income for the period		**787,719,420**	**653,228,413**
Earnings Per Share (EPS)	33	**25.37**	**21.13**
Number of Shares used to Compute EPS		**31,243,627**	**31,243,627**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June 2026

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Fair Value Reserve	Retained Earnings	Total
Balance as at 1 July 2024	**312,436,270**	**4,392,110**	**(8,610,721)**	**3,167,771,833**	**3,475,989,492**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2025	-	-	(6,933,611)	660,162,024	653,228,413
Dividend for the year 30 June 2024 (Cash -63%)				(196,834,850)	(196,834,850)
Balance as at 30 June 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,631,099,007**	**3,932,383,056**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2026			(4,967,378)	792,686,798	787,719,420
Dividend for the year 30 June 2025 (Cash-64%)			-	(199,959,213)	(199,959,213)
Balance as at 30 June 2026	**312,436,270**	**4,392,110**	**(20,511,710)**	**4,223,826,592**	**4,520,143,263**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

CHARTERED ACCOUNTANTS

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CASH FLOWS
For the year ended 30 June 2026

Amount in Taka

	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
Cash Flows From Operating Activities:		
Received from revenue and others	12,435,873,133	10,713,817,824
Payment for operation, expenses & others	(10,951,333,716)	(9,747,244,054)
Miscellaneous income	10,501,552	3,470,820
Cash generated from operations	**1,495,040,968**	**970,044,590**
Cash payment for Income tax paid	(190,610,415)	(174,510,320)
Payment for financial charges	(127,838,224)	(83,710,869)
Net cash generated from operating activities	**1,176,592,329**	**711,823,401**
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(2,761,237,146)	(744,981,021)
Proceeds from sales of motor vehicles	-	(5,232,246)
Profit received from MTDR	(1,574,907)	-
Acquisition of financial assets	-	66,809,029
Profit from MTDR	2,599,404	-
Investment in subsidiary	(200,000,000)	(185,000,000)
Dividend Received/ IBBL-MPB	507,239	1,972,684
Bank profit received	4,528,055	2,506,832
Net cash used in investing activities	**(2,955,177,355)**	**(863,924,722)**
Cash Flows From Financing Activities:		
Payment of dividend	(214,023,231)	(193,870,939)
Long term finance received/(paid) from bank (Net)	236,902,617	344,215,077
Short term finance received/(paid) from bank (Net)	1,726,375,411	(131,254,491)
Net cash generated from financing activities	**1,749,254,797**	**19,089,647**
Increase/(decrease) in cash and cash equivalents	(29,330,229)	(133,011,675)
Cash and cash equivalents at the opening	180,681,788	312,475,845
Foreign exchange fluctuation gain/(loss) on FCAD ERQ Accounts	9,034,412	1,217,618
Cash and cash equivalents at the closing	**160,385,971**	**180,681,788**
NOCFPS (Note 33.02)	**37.66**	**22.78**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Signed as per annexed report on even date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC
Notes to the Consolidated Financial Statements
For the year ended on 30 June 2026

1. Reporting entity

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd. The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and selling them in both local and international market.

1.3 Subsidiary companies

The IBN SINA API Industry Ltd.

The IBN SINA API Industry Ltd. was incorporated in Bangladesh on 16 September 2019 under the Company Act, 1994. The Company involves in manufacturing, trading and other related activities of Active Pharmaceutical Ingredients and other related products.

The IBN SINA Natural Medicine Ltd.

The IBN SINA Natural Medicine Ltd. was incorporated in Bangladesh on 02 December 2020 under the Company Act, 1994. The Company involves in importing, manufacturing, trading and other related activities of natural medicine and other related products.

The IBN SINA Polymer Industry Ltd.

The IBN SINA Polymer Industry Ltd. was incorporated in Bangladesh on 25 March 2021 under the Company Act, 1994. The Company involves in manufacturing, trading and other related activities of Polymer Plastic Bottles, Plastic Tubes, Laminated tubes and other related products.

2. Basis of preparation of financial statements

2.1 Statement on compliance

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and International Accounting Standard (IAS) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by Financial Reporting Council, Bangladesh, the Companies Act, 1994, Securities and Exchange Rules, 1987 and other relevant laws as applicable.

2.2 Basis of Consolidation

The group has prepared separate financial statements and consolidated financial statements for the group separately. The accounts of all the subsidiaries of the Company have been fully consolidated as the Company controls these entities. The Company holds majority of voting right in all of the subsidiaries.

The name of subsidiaries, country of incorporation and proportion of ownership interest are as follows:

Name of Subsidiary	Country of Incorporation	% of Ownership
The IBN SINA API Industry Ltd.	Bangladesh	99.99%
The IBN SINA Natural Medicine Ltd	Bangladesh	99.99%
The IBN SINA Polymer Industry Ltd.	Bangladesh	65%

i) Subsidiaries

Subsidiaries are entities controlled by the Company. The Company 'controls' an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

ii) Non-controlling interests (NCI)

NCI are measured initially at their proportionate share of the acquiree's identifiable net assets at the date of acquisition. Changes in the Company's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

iii) Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

2.3 Other regulatory compliances

The Group is also required to comply with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- The Income Tax Act 2023
- Financial Reporting Act 2015 and FRC Notifications
- The Value Added Tax Act 2012
- The Value Added Tax Rules 2016
- The Drugs Act 1940 and the Drug Rules 1946
- The Drugs (Control) Ordinance 1982
- The Customs Act 1969
- The Stamp Act 1899
- The Bangladesh Securities and Exchange Commission Act 1993
- The Bangladesh Securities and Exchange Commission Rules 1987
- DSE/CSE Rules
- Listing Regulations, 2015
- Bangladesh Labor Act, 2006(as amended to 2018)

2.4 Authorization for issue

The financial statements were authorized for issue by the Board of Directors in its meeting held on 30 September 2026 for publication.

2.5 Basis of measurement

The financial statements have been prepared on going concern basis under the historical cost convention except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

2.6 Accrual basis of accounting

The Group prepares its financial statements, except for cash flow information, using the accrual basis of accounting. Since the accrual basis of accounting is used, the group recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the IFRS conceptual Framework.

2.7 Functional and presentation currency

Functional and presentation currency items included in these financial statements are measured using the currency of the primary economic environment in which the group operates ('the functional currency'). These financial statements are presented in Bangladesh Taka ("BDT") which is also the functional currency of the group. The amounts in these financial statements have been rounded off to the nearest BDT except otherwise indicated.

2.8 Use of estimates and judgments

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

Measurement of fair values
A number of the Company's accounting policies and disclosures require the measurement of fair values for financial assets and liabilities.

The Company has established solid internal control with respect to the measurement of fair values. Significant valuation issues are reported to Audit Committee.

When measuring the fair values of an asset or a liability, the Company uses market observable data as far as possible. When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as 'active' if transactions for the assets or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

2.9 Materiality, aggregation and off setting

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the Group has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of assets or liabilities as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore. No such incident existed during the year.

2.10 Going concern assumption

The financial statements are prepared on the basis of going concern assumption. As per management assessment there is no material uncertainties related to events or conditions which may cast significant doubt upon the Group's ability to continue as a going concern.

2.11 Reporting period

The reporting period of the group covers 12 (twelve) months from 01st July 2025 to 30th June 2026.

2.12 Comparative information

Comparative information has been disclosed in respect of 2025-2026 in accordance with IAS-1 "Presentation of Financial Statements" for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current periods of financial statements. Prior year figure has been re arranged wherever considered necessary to ensure comparability with the current period.

2.13 Consistency

Unless otherwise stated, the accounting policies and methods of computation used in preparation of the financial statements as at and for the year ended 30 June 2026 are consistent with those policies and methods adopted in preparing the financial statements as at and for the year ended 30 June 2026.

3. Significant accounting policies

3.1 Property, plant and equipment

Recognition and measurement

An item shall be recognized as property, plant and equipment's if, and only it is probable that future economic benefits associated with the item will flow to the entity, and the cost of the item can be measured reliably.

Items of property, plant and equipment's are measured at cost less accumulated depreciation as per IAS 16: Property, Plant and Equipment.

The cost of an item of property, plant and equipment comprises its purchase price, import duties and non-refundable taxes, after deducting trade discount and rebates, and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the intended manner. The cost also includes the cost of replacing part of the property, plant and equipment and borrowing costs for term debt availed for the construction/ Implementation of the PPE, if the recognition criteria are met.

The cost of self-constructed assets includes the cost of material and direct labor and other costs directly attributable to bringing the assets to a working condition inclusive of inward freight, duties and non-refundable taxes for their intended use.

Subsequent costs
The subsequent expenditure is only capitalized as part of assets when the useful life or economic benefit or both of that asset is increased provided that it is probable that the future economic benefits embodied within the part will flow to the group and its cost can be measured reliably. The costs of day to day servicing of property, plant and equipment are recognized in the Statement of Profit or loss and other comprehensive income as 'Repair and Maintenance' when it is incurred.

Depreciation on non-current assets
Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provision of IAS 16 "Property, Plant and Equipment". Depreciation is charged on additions made during the year from the month in which those assets are put into ready to use. Depreciation is charged on all the fixed assets except land and land development on reducing balance method at the following rates.

Particular of Assets	Rate of Depreciation
Building	2.5%
Plant & Machinery	10%
Internal Road	10%
Installations	10%
Equipment	10%
Computers	30%
Furniture & Fixtures	10%
Motor vehicles	10%
Motorcycle	20%
Spare & Loose Tools	30%
Library Books	30%
Temporary Construction	30%

Depreciation methods, useful lives and residual values are reviewed after each reporting period. No estimate of Property, Plant and equipment was revised during the year.

Impairment

The carrying amounts of property, plant and equipment are reviewed at each reporting date to determine whether there is any indication of impairment loss. If any such indication exists, recoverable amount is estimated to determine the extent of the impairment loss, if any. Impairment loss is recorded on judgmental basis, for which provision may differ in the future years based on the actual experience.

Disposal of property, plant and equipment

An item of Property, Plant and Equipment is removed from the statement of financial position when it is disposed of or when no future economic benefits are expected from its use or disposal. The gain or loss on the disposal of an item of Property, Plant and Equipment is included in the statement of income of the period in which the de-recognition occurs.

Capital work in progress

Property, plant and equipment under construction/acquisition have been accounted for as capital work-in-progress until construction/acquisition is completed and measured at cost.

3.2 Intangible assets and research and development expenditures

Intangible assets are stated at cost less provisions for amortization and impairments, if any. License, patents, know-how and marketing rights acquired are amortized over their estimated useful lives, using the straight line basis, from the time they are available for use. The cost of acquiring and developing computer

software for internal use and internet sites for external use are capitalized as intangible assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset.

In compliance with the requirements of IAS 38 "Intangible Assets", research, development and experimental costs are usually absorbed as revenue charges as and when incurred. However, the research and development expenditures that is definite to yield benefit to the Group and is material in the Group's and/ local context, are capitalized as per IAS-38.

3.3 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds as per IAS 23: Borrowing Costs.

3.4 Revenue

The Group recognises as revenue the amount that reflects the consideration to which the Group expects to be entitled in exchange for goods or services when (or as) it transfers control to the customer. To achieve that core principle, this standard establishes a five-step model as follows:

- Identify the contract with a customer;
- Identify the performance obligations in the contract;
- Determine the transaction price;
- Allocate the transaction price to the performance obligations in the contract; and
- Recognise revenue when (or as) the entity satisfies a performance obligation.

Considering the five steps model, the Group recognises revenue when (or as) the Group satisfies a performance obligation by transferring promised goods to a customer. Goods are considered as transferred when (or as) the customer obtains control of those goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

Sale of goods

Revenue from the sale of goods is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods. The Group has generally concluded that it is the principal in its revenue arrangements because it typically controls the goods or services before transferring them to the customer.

Profit on bank deposits

Profit on bank deposits have been accounted on accrual basis.

Dividends

Revenue is recognised when the group's right to receive the payment is established, which is generally the date when shareholders of investee company approve the dividend.

3.5 Financial instruments

IFRS 9 sets out requirements for recognising and measuring financial assets, financial liabilities and some contracts to buy or sell non-financial items.

The details of new significant accounting policies and the nature and effect of the changes to previous accounting policies are set out below.

Classification and measurement of financial assets and financial liabilities

IFRS 9 largely retains the existing requirements in IAS 39 for the classification and measurement of financial liabilities. However, it eliminates the previous IAS 39 categories for financial assets of held to maturity, loans and receivables and available for sale.

The adoption of IFRS 9 has not had a significant effect on the group's accounting policies related to financial liabilities. The impact of IFRS 9 on the classification and measurement of financial assets is set out below.

Under IFRS 9, on initial recognition, a financial asset is classified as measured at: amortised cost; Fair Value through Other Comprehensive Income (FVOCI) – debt investment; Fair Value through Other Comprehensive Income (FVOCI) – equity investment; or Fair Value Through Profit or Loss (FVTPL). The classification of financial assets under IFRS 9 is generally based on the business model in which a financial asset is managed and its contractual cash flow characteristics. Derivatives embedded in contracts where the host is a financial asset in the scope of the standard are never separated. Instead, the hybrid financial instrument as a whole is assessed for classification.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

a. it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
b. its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

a. it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
b. its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the group may irrevocably elect to present subsequent changes in the investment's fair value in OCI. This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL.

A financial asset (unless it is a trade receivable without a significant financing component that is initially measured at the transaction price) is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition.

The following accounting policies apply to the subsequent measurement of financial assets.

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and

impairment are recognised in profit or loss. Any gain or loss on de-recognition is recognized in profit or loss. Trade receivables are classified as financial assets measured at amortised cost.

Debt investments at FVOCI

These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On de-recognition, gains and losses accumulated in OCI are reclassified to profit or loss.

Equity investments at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are never reclassified to profit or loss.

Impairment of financial assets

IFRS 9 replaces the 'incurred loss' model in IAS 39 with an 'expected credit loss' (ECL) model. The new impairment model applies to financial assets measured at amortised cost, contract assets and debt investments at FVOCI, but not to investments in equity instruments.

The financial assets at amortised cost consist of trade receivables, cash and cash equivalents, and corporate debt securities. The group measures loss allowances at an amount equal to ECL from trade receivables.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on The group's historical experience and informed credit assessment and including forward-looking information.

The group considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the group in full, without recourse by The group to actions such as realizing security (if any is held).

Measurement of Expected Credit Losses (ECL)

ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the group expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

Presentation of impairment

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is recognised in OCI, instead of reducing the carrying amount of the asset.

Impairment losses related to trade receivables and others, including contract assets, are presented separately in the notes to the financial statement.

3.6 Impairment of Non-financial assets

The carrying amounts of the Group's non-financial assets (other than inventories) are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated in order to determine the extent of impairment loss (if any). Where it is not possible to determine the recoverable amount of an individual asset, the Group estimates the recoverable amount of the Cash Generating Unit (CGU) to which the asset belongs. An impairment loss is recognised if the carrying amount of an asset or its CGU exceeds its recoverable amount.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

Impairment losses are recognised in profit or loss. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognised.

3.7 Inventories

Inventories consisting of raw materials, work in progress, finished goods are valued at lower of cost and net realizable value. Cost of inventories include expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Cost of inventories is determined by using the weighted average cost formula. Where necessary, allowance is provided for damaged, obsolete and slow-moving items to adjust the carrying amount of inventories to the lower of cost and net realizable value. Net realizable value is based on estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

3.8 Cash and cash equivalents

Cash and cash equivalents consists of cash on hand and with banks on current accounts, deposit accounts and short term investments which are held and available for use by the group without any restriction. There is insignificant risk of change in value of the same.

3.9 Earnings per Share (EPS)

Earnings per Share (EPS) are calculated in accordance with the International Accounting Standard IAS- 33 "Earnings Per Share".

Basic earnings per share
Basic earnings per share is calculated by dividing the profit or loss attributable to ordinary equity holders of the entity by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share

For the purpose of calculating diluted earnings per shares, an entity adjusts profit or loss attributable to each ordinary equity holders of the entity, and weighted average number of shares outstanding, for the effects of all dilutive potential ordinary shares. Diluted EPS is only calculated where the group has commitment to issue ordinary share in future at reporting date. No such commitment is hold by group at reporting date.

3.10 Foreign currency transactions

Foreign currency transactions are recorded, on initial recognition in the functional currency at the spot exchange rate ruling at the transaction date.
At the end of each reporting period in compliance with the provision of IAS 21: The Effects of Changes in Foreign Exchange Rates.

a) Foreign currency monetary items are translated using the closing rate.
b) Non-monetary items that are measured in terms of historical costs in a foreign currency are translated using the exchange rate at the date of the transaction.
c) Non-monetary items that are measured at fair value in a foreign currency is translated using the exchange rate at the date when the fair value is determined.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rate different from those at which they were translated on initial recognition during the period or in previous financial statements is recognized in profit or loss in the period in which they arise.

Amount in FCAD ERQ Account and any other foreign currency balance have been translated into taka at the reporting date at the exchange rate prevailing on that date and gain/(loss) have been accounted for as other income/(loss) in statement of profit or loss and comprehensive income.

3.11 Employee benefits

The Company maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective trust deeds and rules. Both of the plans are funded and are recognised/approved under Income Tax Ordinance 1984 from National Board of Revenue (NBR).

(a) Defined contribution plan (provident fund)

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contribution to defined contribution plans are recognised as an employee benefit expense in profit or loss in the period during which related services are rendered by employees. Advance contributions are recognised as an asset to the extent that a cash refund or a reduction in future payment is available.

The Company has a separate recognised provident fund scheme. All permanent employees of The Company contribute 10% of their basic salary to the provident fund and the group makes matching contributions.

The group recognises contribution to defined contribution plan as an expense when an employee has rendered related services in exchange for such contribution. The legal and constructive obligation is limited to the amount The Company agrees to contribute to the fund.

(b) Defined benefit plan (gratuity)

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The employee gratuity plan is considered as defined benefit plan as it meets the recognition criteria. The group's obligation is to provide the agreed benefits to current and former employees. The net defined benefit liability/(asset) in respect of a defined benefit plan is recognised in the statement of financial position.

Current service cost, past service cost and gain/loss on settlement and net interest on the net defined benefit liability/(asset) are recognized in profit or loss. Service cost and gain/loss on settlement are classified as personnel expense.

The gratuity is calculated for all the employees prescribed by the rates as per Labor Act 2006 (as amended to 2018) for their service with the group. The gratuity fund is administered by the Board of Trustees.

Superannuation Fund:

The Company has established a Superannuation Fund in the year 2013 to extend financial help to the employees and their family members as per rules in case of severe diseases, physical disability, death and retirement. Every year the Company contributed to the Fund and will continue its support in the coming days.

Workers' Profit Participation Fund (WPPF)

The Company provides 5% of its profit before Tax after charging contribution to WPPF in accordance with Bangladesh Labor Act, 2006 (as amended to 2018)

(c) Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

3.12 Accruals, provisions and contingencies

(a) Accruals
Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees. Accruals are reported as part of trade and other payables.

(b) Provisions
A provision is recognised in the statement of financial position when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the reporting date. Where the group expects some or all of a provision to be reimbursed, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the income statement net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. During the reporting year the group has made sufficient provisions where applicable.

(c) Contingencies
A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the group; or a present obligation that arises from past events but is not recognised because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or the amount of the obligation cannot be measured with sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the group. At the reporting date the group does not have any contingent asset.

Contingent liabilities and assets are not recognised in the statement of financial position of the group.

3.13 Operating Segments

No geographical segment reporting is applicable for the Group as required by IFRS 08: Operating Segments, as the Group operates in a single geographical area and has a single business line of product i.e. manufacturing and selling of medicine.

3.14 Statement of cash flows

The Statement of Cash Flows has been prepared in accordance with the requirements of IAS 7: Statement of Cash Flows. The cash generating from operating activities has been reported using the Direct Method as prescribed by the Securities and Exchange Rules, 1987 and as the benchmark treatment of IAS 7 whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.

3.15 Related party disclosures
As per International Accounting Standards IAS-24: 'Related Party Disclosures', parties are considered to be related if one of the parties has the ability to control the other party or exercise significant influence

over the other party in making financial and operating decisions. The Group carried out transactions in the ordinary course of business on an arm's length basis at commercial rates with its related parties. Related party disclosures have been given in Note 36.

3.16 Income tax

Income tax expense comprises current and deferred taxes. Income tax expense is recognised in profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity in accordance with IAS 12: Income Tax.

3.17 (a) Current tax

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous periods. The tax rate used for the reporting period was 20% as a publicly traded company.

3.17 (b) Deferred tax

Deferred tax is recognized as income or an expense amount within the tax charge, and included in the net profit or loss for the period. Deferred tax relating to items dealt with other comprehensive income is recognized as tax relating to other comprehensive income within the statement of profit or loss and other comprehensive income.

Taxable Temporary difference

A deferred tax liability is recognised for all taxable differences, except to the extent that the deferred tax liability arises from the initial recognition of goodwill; or the initial recognition of an asset or liability in a transaction which is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

Deductible temporary difference

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilized, unless the deferred tax asset arises from the initial recognition of an asset or liability in a transaction that is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

3.18 Events after the reporting period

Events after the reporting period that provide additional information about the group's position at the statement of financial position date are reflected in the financial statements as per International Accounting Standards IAS-10: 'Events after the Reporting Period'.

All material events occurring after the balance sheet date have been considered and where necessary, adjusted for or disclosed.

3.19 Compliance with financial reporting standards as applicable in Bangladesh

The Group as per Para-12 of Securities & Exchange Rule-1987, with the following International Accounting Standards (IASs) and International Financial Reporting Standards (IFRS) as adopted by The Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by the Financial Reporting Council, Bangladesh in preparing the financial statements.

Sl. No.	IAS No.	IAS Title	Compliance Status
1	1	Presentation of Financial Statements	Complied
2	2	Inventories	Complied
3	7	Statement of Cash Flows	Complied
4	8	Accounting Policies, Changes in Accounting Estimates and Errors	Complied
5	10	Events after the Reporting Period	Complied
6	12	Income Taxes	Complied
7	16	Property, Plant & Equipment	Complied
8	19	Employee Benefits	Complied
9	20	Accounting for Government Grants and Disclosure of Government Assistance	Not Applicable
10	21	The Effects of Changes in Foreign Exchange Rates	Complied
11	23	Borrowing Cost	Complied
12	24	Related Party Disclosures	Complied
13	26	Accounting and Reporting by Retirement Benefit Plans	Not Applicable
14	27	Separate Financial Statements	Complied
15	28	Investments in Associates and joint ventures	Not Applicable
16	29	Financial Reporting in Hyperinflationary Economics	Not Applicable
17	31	Interest in Joint Ventures	Not Applicable
18	32	Financial Instruments: Presentation	Complied
19	33	Earnings per Share	Complied
20	34	Interim Financial Reporting	Complied
21	36	Impairment of Assets	Complied
22	37	Provisions, Contingent Liabilities and Contingent Assets	Complied
23	38	Intangible Assets	Complied
24	40	Investment Property	Not Applicable
25	41	Agriculture	Not Applicable

Sl. No.	IFRS No.	IFRS Title	Compliance Status
1	1	First-time adoption of International Financial Reporting Standards	Not Applicable
2	2	Share-based Payment	Not Applicable
3	3	Business Combinations	Not Applicable
4	4	Insurance Contracts	Not Applicable
5	5	Non-current Assets Held for Sale and Discontinued Operations	Not Applicable
6	6	Exploration for and Evaluation of Mineral Resources	Not Applicable
7	7	Financial Instruments: Disclosures	Complied
8	8	Operating Segments	Complied
9	9	Financial Instrument	Complied
10	10	Consolidated Financial Statements	Complied
11	11	Joint Arrangements	Not Applicable
12	12	Disclosure of Interests in other Entities	Complied
13	13	Fair Value Measurement	Complied
14	14	Regulatory Deferral Accounts	Not Applicable
15	15	Revenue from Contracts with Customers	Complied
16	16	Lease	Complied

3.20 Leases

Right-of-use Assets and Lease Liabilities as Leasee

The Company assesses whether a contract is or contains a lease, at inception of the contract. As a Leasee, the Company recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less). For these leases, the Company recognizes the lease payments as an expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

The Company recognizes a right-of-use asset at the lease commencement date. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received, and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The right-of-use assets are presented as a separate line in the statement of financial position.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate.

The lease liability is presented as a separate line in the statement of financial position.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

Finance Lease or operating lease as Lessor

The company as a lessor classify its leases as either an operating lease or a finance lease.

3.21 Investment in Subsidiary

The group's investment in subsidiaries is accounted for in the separate financial statements as per IAS 27: "Separate Financial Statements" using the cost method. Dividends from the subsidiaries are recognized in the separate financial statements of the Company when the Company's right to receive the dividend is established. The dividend is recognized in profit or loss unless the Company elects to use the equity method, in which case the dividend is recognized as a reduction from the carrying amount of the investment.

3.22 Dividend Distribution

Final dividend distributions to the Company's shareholders are recognized as a liability in the financial statements in the period in which the dividends are approved by the Company's shareholders at the Annual General Meeting, while interim dividend distributions are recognized in the period in which the dividends are declared and paid.

3.23 Adoption of new and amended International Financial Reporting Standards

The new and amended standards are not expected to have a material impact on the Company's financial statements.

	Amount	
	30 June 2026	30 June 2025

04. PROPERTY, PLANT AND EQUIPMENT:

Cost :		
Opening balance	4,169,069,419	3,956,915,644
Addition during the year	137,224,204	215,232,652
Disposal/Adjustment during the year	-	(3,078,877)
Closing balance	**4,306,293,623**	**4,169,069,419**
Accumulated Depreciation:		
Opening balance	1,737,415,883	1,554,782,910
Charged during the year	179,260,907	185,554,095
Disposal/Adjustment during the year	-	(2,921,123)
Closing balance	**1,916,676,789**	**1,737,415,883**
Closing balance of written Down Value (WDV)	**2,389,616,834**	**2,431,653,536**

i. The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company. Please see the annexure -A.
ii. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:

The IBN SINA Pharmaceutical Industry PLC	2,389,616,834	2,431,653,536
The IBN SINA API Industry Ltd.	164,672,352	142,245,156
The IBN SINA Polymer Industry Ltd.	2,380,977	2,288,106
The IBN SINA Natural Medicine Ltd.	81,842,005	79,332,838
	2,638,512,168	**2,655,519,636**

05. CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	711,323,283	366,379,612
Add: Addition during the year	201,319,709	344,943,671
Less: Transferred to property, plant and equipment	-	-
Closing balance	**912,642,992**	**711,323,283**
B) Machinery in transit and installation		
Opening balance	398,469,652	213,664,954
Add: Addition during the year	2,710,341,137	310,149,835
Less: Transit closed during the year	(269,073,756)	(125,345,137)
	2,839,737,033	**398,469,652**
Other Goods-In-Transit	27,455,091	46,029,239
	3,779,835,116	**1,155,822,174**

i) A new Factory is being constructed to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. That is why construction working progress and machinery in transit and installation increased significantly.
ii) The amount of machinery in transit represents the amount for opening the LC for the procurement of machineries for newly constructed factory building and increasing production capacity of existing factory which have not received yet .
iii) Amount of borrowing cost capitalised during the year is Tk. 5,133,563
iv) Capitalisation rate used is 7.50% for machinery upas.
v. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.

05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	939,492,119	465,469,776
Addition during the year	341,426,379	474,022,343
Less: Transferred to property, plant and equipment	-	-
Closing balance	**1,280,918,499**	**939,492,119**
B) Machinery in transit and installation		
Opening balance	946,837,388	673,427,435
Add: Addition during the year	2,799,698,356	398,755,090
Less: Transit closed during the year	(269,073,756)	(125,345,137)
	3,477,461,987	**946,837,388**
Other Goods-In-Transit	27,455,091	46,029,239
	4,785,835,577	**1,932,358,746**

05.B RIGHT-OF-USE ASSETS:

Cost:		
Opening balance	130,252,602	130,252,602
Addition during the year	-	-
Disposal/Adjustment during the year	-	-
Closing balance	**130,252,602**	**130,252,602**

		Amount	
		30 June 2026	30 June 2025
	Accumulated Depreciation:		
	Opening balance	97,179,891	72,375,357
	Charged during the year	24,804,533	24,804,533
	Disposal/Adjustment during the year	-	-
	Closing balance	**121,984,424**	**97,179,891**
	Closing balance of Written Down Value (WDV)	**8,268,178**	**33,072,711**
06.	**FINANCIAL ASSESTS (NON-CURRENT PORTION):**		
	Exim Bank PLC	1,140,000	2,090,000
	First Security Islami Bank PLC	3,896,900	7,793,800
	Shahjalal Islami Bank PLC	1,854,000	1,699,500
	Al-Arafah Islami Bank PLC	1,676,325	1,849,365
	Social Islami Bank PLC	520,929	1,284,958
	Islami Bank Bangladesh PLC in MPB	3,050,055	2,939,895
		12,138,209	**17,657,518**

The above investment in marketable securities are designated as Fair Value thought other comprehensive income by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. Please see the annexure B.

06.A	**CONSOLIDATED FINANCIAL ASSESTS (NON-CURRENT PORTION):**		
	Exim Bank PLC	1,140,000	2,090,000
	First Security Islami Bank PLC	3,896,900	7,793,800
	Shahjalal Islami Bank PLC	1,854,000	1,699,500
	Al-Arafah Islami Bank PLC	1,676,325	1,849,365
	Social Islami Bank PLC	520,929	1,284,958
	Islami Bank Bangladesh PLC in MPB	3,050,055	2,939,895
	Investment in API Industrial Park Services Ltd.	29,000,000	29,000,000
		41,138,209	**46,657,518**
07	**INVESTMENT IN SUBSIDIARY :**		
	The IBN SINA API Industry Ltd.	799,999,800	669,999,800
	The IBN SINA Natural Medicine Ltd.	238,169,670	238,169,670
	The IBN SINA Polymer Industry Ltd.	200,000,000	130,000,000
		1,238,169,470	**1,038,169,470**

i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk. 12.00 crore has been paid as a part of share capital.

ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.

iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company.

iv) Investment in subsidiary increased due to fulfilling subsidiary companies investment need.

08.	**FINANCIAL ASSESTS (CURRENT PORTION):**		
	Opening Balance	22,500,000	89,500,000
	Closed-during the year	-	(67,000,000)
	Investment in MTD	**22,500,000**	**22,500,000**
08.A	**CONSOLIDATED FINANCIAL ASSESTS (CURRENT PORTION):**		
	Investment in MTD	**22,500,000**	**22,500,000**
08.1	**INVENTORIES:**		
	Raw materials	713,243,317	661,133,854
	Packing materials	269,533,870	230,992,875
	Work-in-process	105,219,105	97,983,312
	Finished goods	344,256,222	357,701,249
	Physicians' samples	6,578,305	5,836,177
	Pad & literature	4,719,383	4,127,335
	Spares & stores	429,379	360,234
	Indirect materials	515,942	463,694
	Printing & stationery	448,072	393,698
	Laboratory chemicals	261,565	236,318
	Material in transit	293,589,728	244,546,564
		1,738,794,887	**1,603,775,310**

i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, milligram and ton as such quantity can not be inserted.

	Amount	
	30 June 2026	30 June 2025

ii) There is no damage goods or slow moving item in the inventory list.

iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.

iv) Inventory for Raw materials , Packing materials, Work In Process, Finished goods and pad & literature changed during the period for ensuring smooth supply of products.

08.B CONSOLIDATED INVENTORIES:

Raw materials	799,860,851	768,094,729
Packing materials	295,680,022	245,848,438
Work-in-process	126,653,151	111,124,876
Finished goods	440,506,971	424,409,351
Physicians' samples	9,717,892	8,481,886
Pad & literature	4,719,383	4,127,335
Spares & stores	429,379	360,234
Indirect materials	515,942	463,694
Printing & stationery	448,072	393,698
Laboratory chemicals	261,565	236,318
Material in transit	293,589,728	244,546,564
	1,972,382,955	**1,808,087,123**

09. TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	170,988,026	181,402,168
Receivable from provident fund (PF)	602,059	304,966
Dividend receivable	341,496	-
Profit receivable from MTD	4,966,878	3,391,971
Other receivable-toll charge	3,346,594	2,497,081
	180,245,053	**187,596,187**

i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due from the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.

ii) Other receivable increased during the year as few months toll charge bill remain receivable.

The lifetime expected credit loss provision for trade receivables is as follows:

30-Jun-26	Current	1-30 days past due	31-90 days past due	91-120 days past due	120-180 days past due	Above 180 days past due	Total
ECL rate	0%	0.20%	0.50%	5.00%	10.00%	20.00%	
Gross carrying amount	3,597,055	113,642,996	43,485,156	2,846,581	1,501,163	8,315,290	173,388,241
Loss Provision	-	227,286	217,426	142,329	150,116	1,663,058	2,400,215

09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	180,517,362	189,858,588
Receivable from provident fund (PF)	602,059	304,966
Dividend receivable	341,496	-
Profit receivable from MTD	4,966,878	3,391,971
Other receivable-toll charge	3,346,594	2,497,081
	189,774,389	**196,052,607**

10. ADVANCES, DEPOSITS & PREPAYMENTS :

a. Advances against		
Salary	6,102,581	5,482,341
Expenses/works/others	12,433,414	12,433,414
Depot rent	6,816,187	6,727,985
Motor cycles-to employees	66,216,715	42,143,838
Building (Flat) - Concord Lily Height'S	105,000,000	-
Others	706,533	706,533
	197,275,431	**67,494,111**
b. Income tax		
Opening balance	374,539,128	200,028,807
Addition	190,610,415	174,510,320
Adjusted during the year	-	-
	565,149,543	**374,539,128**
c. Deposits		
Security money	**20,580,535**	**21,275,544**
d. Pre payments		
Value Added Tax	**715**	**6,683**
	783,006,223	**463,315,466**

		Amount	
		30 June 2026	30 June 2025
10.1	**MATURITY ANALYSIS:**		
	Realisable/adjustable within one year.	749,291,153	429,600,396
	Realisable/adjustable after one year.	33,715,070	33,715,070
		783,006,223	**463,315,466**

i) The company did not give any advance, deposit and prepayment to the director's of the company, subsidiary, associates and other connected party and employees advances are realised in normal course of business.
ii) Advance against works, salary and motor cycle increased during this year to meet up business needs.
iii) Advance income tax increased during this period to meet up regulatory requirement.
iv) Security money increased during this year as security money was paid to various parties for business purpose.

10.A	**CONSOLIDATED ADVANCES, DEPOSITS & PREPAYMENTS :**		
	a. Advances against		
	Salary	16,459,616	9,555,942
	Expenses/works/others	13,573,966	31,119,648
	Depot rent	6,816,187	6,727,985
	Motor cycles-to employees	78,047,148	61,431,738
	Building (Flat) - Concord Lily Height'S	105,000,000	-
	Others	2,991,698	2,101,636
		222,888,615	**110,936,949**
	b. Income tax		
	Opening balance	404,148,716	223,481,751
	Addition	205,988,714	180,666,965
		-	-
		610,137,431	**404,148,716**
	c. Deposits		
	Security money	**21,635,232**	**22,330,241**
	d. Pre payments		
	Value Added Tax	**715**	**6,683**
	Insurance premium		
		854,661,993	**537,422,590**
10.A.1	**MATURITY ANALYSIS:**		
	Realisable/adjustable within one year.	820,696,923	503,707,520
	Realisable/adjustable after one year.	33,965,070	33,715,070
		854,661,993	**537,422,590**
11.	**CASH & CASH EQUIVALENTS:**		
	a. Cash in hand	7,077,597	6,613,494
	b. Cash at bank	149,773,374	170,528,294
	c. Imprest cash	3,535,000	3,540,000
		160,385,971	**180,681,788**
	CASH AT BANKS:		
	a. Islami Bank Bangladesh PLC		
	In SND Accounts	58,932,119	107,552,199
	In MSA Accounts	850,241	831,753
	In FCAD ERQ Accounts	1,117,739	1,316,416
	Cash with IBBL Securities Ltd.	374	524
	b. Al-Arafah Islami Bank PLC in SND Accounts	56,874,197	43,945,485
	c. Prime Bank PLC in Current Account (Islamic banking branch)	29,396	29,396
	d. Shimanto Bank PLC in SND Account	16,435	16,435
	e. First Security Islami Bank PLC in SND Accounts	1,488,227	1,411,967
	f. Sonali Bank PLC in ERQ Account	360,537	360,390
	g. Sonali Bank PLC in STD Account	1,068,682	1,052,377
	h. City Bank PLC	24,228,574	359,518
	i. Pubali Bank PLC	1,626,666	4,490,038
	j. Standard Chartard Bank PLC	360,419	-
	h. Standard Bank PLC	2,819,768	9,161,796
		149,773,374	**170,528,294**

i) The bank reconciliation was performed at the year end and found in order.
ii) Physical cash counting was taken place at the year end and no surplus or deficit was found.
iii) Cash and cash equivalent decreased due to settlement of shorterm loan.

11.A	**CONSOLIDATED CASH & CASH EQUIVALENTS:**		
	a. Cash in hand	8,616,897	7,137,453
	b. Cash at bank	285,023,263	304,095,694
	c. Imprest cash	3,665,000	3,670,000
		297,305,160	**314,903,147**

		Amount	
		30 June 2026	30 June 2025

12. SHARE CAPITAL:

Authorized:

50,000,000 Ordinary Shares of Tk. 10 each	500,000,000	500,000,000
Issued, Subscribed & Paid-Up :		
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash	312,436,270	312,436,270

The Shareholdings consist of :

Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,843,312	44.31%
Institution	218	8,052,066	25.77%
General Public	12,314	9,348,249	29.92%
	12,533	31,243,627	100.00%

The distribution schedule showing the number of share holders and their share holdings as on 30.06.2026 are as follows:

Range of Holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	9,977	1,727,958	5.53%
500 to 5,000 shares	2,188	3,299,599	10.56%
5,001 to 10,000 shares	188	1,341,142	4.29%
10,001 to 20,000 shares	85	1,145,793	3.67%
20,001 to 30,000 shares	24	550,758	1.76%
30,001 to 40,000 shares	15	525,794	1.68%
40,001 to 50,000 shares	8	360,545	1.15%
Above 50,000 shares	48	22,292,038	71.35%
	12,533	31,243,627	100.00%

The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quoted at Tk. 294.10 in the Dhaka Stock Exchange Limited as at 30.06.2026 and at Tk. 294.00 in the Chittagong Stock Exchange Limited as 30.06.2026 respectively.

13. TAX HOLIDAY RESERVE:	**4,392,110**	**4,392,110**

This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.

14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:

Closing market value of marketable securities	12,138,209	17,657,518
Less: Cost of marketable securities	34,928,997	34,928,997
Unrealized gain (loss) before adjustment of deferred tax	**(22,790,788)**	**(17,271,479)**
Less: Deferred tax on unrealized gain/(loss)	2,279,079	1,727,148
Net unrealized gain/(loss) on marketable securities	**(20,511,709)**	**(15,544,331)**

15. RETAINED EARNINGS:

Opening Balance	3,631,099,007	3,167,771,833
Dividend paid	(199,959,213)	(196,834,850)
Add : Net profit during the year	792,686,798	660,162,024
	4,223,826,592	**3,631,099,007**

15.A CONSOLIDATED RETAINED EARNINGS:

Opening Balance	3,625,617,615	3,189,263,114
Dividend paid	(199,959,213)	(196,834,850)
Add: Net profit during the year	794,633,174	633,189,350
	4,220,291,576	**3,625,617,615**

15.B NON CONTROLLING INTEREST:

The IBN SINA API Industry Ltd.	200	200
The IBN SINA Natural Medicine Ltd.	3,000	3,000
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)	140,000,000	70,000,000
Add: Share of Profit/(Loss)	(762,477)	943,396
	139,240,723	**70,946,596**

16. LONG TERM FINANCE :

i) From Al-Arafah Islami Bank PLC. Secured (Under Hire Purchase Shirkatul Melk-HPSM)	838,907,795	565,545,640
ii) From Pubali Bank PLC (Long Term -H.P.S.M) Pharma	323,752,886	307,123,287
Current maturity transferred to current liability		
iii) From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shirkatul Melk) Note -21	(172,534,991)	(119,445,855)
LONG TERM FINANCE - net off current maturity	**990,125,690**	**753,223,072**

i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial position @ 13%, 12.50% & 11% of profit.

ii) The loan was taken from Al-Arafah Islami Bank PLC and Pubali Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import capital

iii) HPSM is repayable in 84 monthly equal installment.

iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.

	Amount	
	30 June 2026	30 June 2025

v) The company achieved AA+ rating in long term and ST-1 for short term from Alpha credit rating Ltd.
vi) For construction purpose company has taken loan from Pubali Bank PLC that is why long lerm loan increased significantly.
vii) Information regarding loan fall due after five years.

Loan fall due from 2 to 5 years	559,271,863	377,030,427
Loan fall due from 6 to more years	430,853,827	376,192,645
	990,125,690	753,223,073

16.A CONSOLIDATED LONG TERM FINANCE :

The IBN SINA Pharmaceutical Industry PLC	990,125,689	753,223,072
The IBN SINA API Industry Ltd.	207,106,867	221,482,304
	1,197,232,556	**974,705,376**

17. EMPLOYEE BENEFIT OBLIGATIONS:

Opening Balance	990,546	1,185,180
Provision during the year	117,017,617	97,491,986
Less: Paid during the year	(117,500,442)	(97,686,620)
	507,721	**990,546**

17. A CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:

Opening Balance	990,546	1,185,180
Provision during the year	156,776,143	137,250,512
Less: Paid during the year	(157,258,968)	(137,445,146)
	507,721	**990,546**

17. B LEASE LIABILITIES:

Opening Balance	23,798,698	50,336,979
Finance charge	1,282,480	3,692,459
Paid during the year	(25,081,178)	(30,230,740)
Closing balance	**0.00**	**23,798,698**
Less : Transferred to current maturity	(0.00)	(23,798,698)
	-	-

i) The company has lease against its Head Office and its Depot at Mohammadpur and Mirpur, Dhaka respectively.
ii) Lease period is upto 31.10.2026
iii) Advance amount paid Tk. 11,661,000
iv) Monthly adjustment Tk. 50,000

18. DEFERRED TAX LIABILITIES/(ASSETS):

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax (expense)/income have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability/(assets)
Property, plant and equipment	2,389,616,834	1,921,535,868	468,080,965	20.00%	93,616,193
Gratuity	118,008,163	117,500,442	(507,721)	20.00%	(101,544)
Lease	8,268,178	7,309,133	959,044	20.00%	191,809
Unrealized gain on marketable securities	(22,790,788)	-	(22,790,788)	10.00%	(2,279,079)
Bad Debt provision	2,400,215	-	(2,400,215)	20.00%	(480,043)
As at 30 June 2026	**2,495,502,602**	**2,046,345,444**	**443,341,286**		**90,947,336**
Property, plant and equipment	2,431,653,536	1,943,389,552	488,263,984	20.00%	97,652,797
Gratuity	98,677,167	97,686,620	(990,547)	20.00%	(198,109)
Lease	9,274,013	12,994,333	(3,720,320)	20.00%	(744,064)
Unrealized gain/(loss) on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad Debt provision	1,358,626		(1,358,626)	20.00%	(271,725)
As at 30 June 2025	**2,523,691,863**	**2,054,070,505**	**464,923,012**		**94,711,750**

DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	90,947,336	94,711,750
Opening balance of deferred tax liability	94,711,750	99,285,702
Total deferred tax expenses	**(3,764,414)**	**(4,573,952)**
Less/Add: Deferred tax expenses related to other comprehensive income	551,931	770,401
	(3,212,483)	**(3,803,551)**

	Amount	
	30 June 2026	30 June 2025

19. CONSOLIDATED DEFERRED TAX LIABILITIES/(ASSETS):

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability/(assets)
Property, plant and equipment	2,638,512,168	2,161,780,901	476,731,266	20% To 27.50%	95,857,055
Gratuity	161,527,536	161,019,815	(507,721)		(101,544)
Accrued profit on mtdr	-	-	-	27.50%	-
Lease	8,011,893	7,309,133	702,759		102,427
Unrealized gain/(loss) on marketable securities	(22,790,788)	-	(22,790,788)	10%	(2,349,557)
Bad Debt provision	2,400,215	-	(2,400,215)		(480,043)
As at 30 June 2026	**2,787,661,024**	**2,330,109,850**	**451,735,302**		**93,028,338**
Property, plant and equipment	2,653,231,530	2,157,701,612	495,529,918	20% To 27.50%	99,530,336
Gratuity	148,665,292	147,674,745	(990,547)		(198,109)
Accrued profit on mtdr	-	-	-	27.50%	-
Lease	8,813,099	12,994,333	(4,181,234)		(870,815)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10%	(1,727,148)
Bad Debt provision	1,358,626	-	(1,358,626)		(271,725)
As at 30 June 2025	**2,794,797,068**	**2,318,370,690**	**471,728,033**		**96,462,538**

DEFERRED TAX EXPENSES/(INCOME) :		
Closing balance of deferred tax liability	93,028,338	96,462,538
Opening balance of deferred tax liability	96,462,538	101,180,185
Total deferred tax expenses	**(3,434,200)**	**(4,717,647)**
Less/Add: Deferred tax expenses related to other comprehensive income	551,931	770,401
	(2,882,270)	**(3,947,246)**

20. SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/TR)	2,607,058,173	933,771,898
	2,607,058,173	**933,771,898**

i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of statement of financial position @ 15% of profit and 0.20% commission per quarter to be paid.
ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite investment facilities LC/MPI/MIB/ TR/UPAS/ Baimuajjal
iii) Short term loan is repayable within twelve months.
iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.
v) Short term finance decreased significantly due to settlement of short term LCs.

20.A CONSOLIDATED SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/TR)	2,607,058,173	933,771,898
B. The IBN SINA API Industry Ltd.	29,306,186	19,911,341
	2,636,364,359	**953,683,239**

21. CURRENT PORTION OF LONG TERM FINANCE:

i) From Al-Arafah Islami Bank PLC.-Secured (Note-16) (Under Hire Purchase Shirkatul Melk)	**172,534,991**	**119,445,855**

The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank PLC which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.

22. TRADE AND OTHER PAYABLES :

Payable to suppliers		705,359,343	354,248,263
Provisions	Note-22.1	166,819,427	187,977,710
Accrued expenses		303,940,483	178,532,052
Security money received from employees and others		12,437,585	11,517,972
Workers' profit participation fund & welfare fund		49,806,420	42,953,850
		1,238,363,259	**775,229,847**

i) Payable to suppliers and accrued expenses decreased this year to meetup business need.
ii. Accrued expenses increased du to payment made same bill after reporting period.

22.1 PROVISIONS:

Opening balance	187,977,710	144,607,133
Provisions made during the year	166,819,427	187,977,710
Provisions used during the year	(187,977,710)	(144,607,133)
Closing balance	**166,819,427**	**187,977,710**

		Amount	
		30 June 2026	30 June 2025
22.A	**CONSOLIDATED TRADE AND OTHER PAYABLES :**		
	Payable to suppliers	760,786,943	396,181,410
	Provisions	166,819,427	187,977,710
	Accrued expenses	314,015,709	203,253,644
	Security money received from employees and others	12,437,585	11,517,972
	Workers' profit participation fund & welfare fund	52,979,904	43,358,391
		1,307,039,568	**842,289,127**
22.A.1	**UNCLAIMED DIVIDEND :**		
	Opening	42,104,508	39,140,597
	Addition	199,959,213	196,834,850
	Paid to share holders	(214,023,231)	(186,963,608)
	Paid to Capital Market Stabilisation Fund	-	(6,907,331)
		28,040,490	**42,104,508**
22.A.2	**UNCLAIMED DIVIDEND :**		
	Year-wise break-up of the above is as follows :		
	2021-22	-	12,953,290
	2022-23	10,966,874	15,606,678
	2023-24	9,905,202	13,544,540
	2024-25	7,168,414	-
		28,040,490	**42,104,508**
23.	**PROVISION FOR CORPORATE TAX:**		
	Opening balance	458,584,929	255,866,409
	Current tax provision	206,654,091	202,718,520
		665,239,020	**458,584,929**
	Adjusted during the year	-	-
		665,239,020	**458,584,929**
23.A	**CONSOLIDATED PROVISION FOR CORPORATE TAX:**		
	Opening balance	495,245,930	284,580,559
	Current tax provision	224,535,706	210,665,371
		719,781,636	**495,245,930**
	Adjusted during the year	-	-
		719,781,636	**495,245,930**

i) Income tax liability increased during this year as current tax provision went up with higher profit.
ii) Tax rate is applicable as finance act 2025 and 2026.

		Amount	
		01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
24.	**REVENUE:**		
	Local revenue	12,234,822,515	10,537,719,504
	Export revenue	184,057,541	188,237,518
		12,418,880,056	10,725,957,022
24.A	**CONSOLIDATED REVENUE:**		
	The IBN SINA Pharmaceutical Industry PLC	12,418,880,056	10,725,957,022
	The IBN SINA Natural Medicine Ltd..	1,480,912,378	1,157,636,691
		13,899,792,434	11,883,593,713

The above sales represent the following :

Product Group	Unit	2025-2026		2024-2025	
		Quantity	Amount	Quantity	Amount
Tablet	Pcs	1,229,237,911	5,151,525,918	1,094,808,761	4,198,049,398
Capsule	Pcs	415,679,238	2,853,025,236	371,632,360	2,439,756,300
Dry syrup / ORS	Bottle	26,002,805	581,367,128	27,924,900	544,913,682
Liquid Bottles	Bottle	32,329,710	2,811,158,084	27,797,817	2,295,027,321
Drops	Pcs	7,359,975	585,600,313	5,723,391	507,238,083
Ointment	Pcs	8,995,541	571,991,775	7,834,010	419,163,600
Injection	Pcs	10,305,718	1,353,213,524	8,190,285	1,479,445,329
Total Value			**13,907,881,978**		**11,883,593,713**

24.B.	**Timing of revenue recognition:**		
	Products transferred at a point in time	12,418,880,056	10,725,957,022
	Products and services transferred over time	-	-
		12,418,880,056	10,725,957,022
25.	**COST OF GOODS SOLD :**		
	This is arrived at as follows:		
	Raw materials consumed Note-25.1	3,883,201,045	3,406,401,899
	Packing materials consume Note-25.2	1,989,363,352	1,733,049,756
		5,872,564,397	5,139,451,655
	Opening work-in-process	97,983,312	103,450,764
	Closing work-in-process	-105,219,105	-97,983,312
	Total Consumption	5,865,328,604	5,144,919,107
	Manufacturing expenses Note-26	1,556,365,257	1,330,536,247
	Cost of Production	7,421,693,861	6,475,455,354
	Opening finished goods	357,701,249	356,044,770
	Closing finished goods	-344,256,222	-357,701,249
		7,435,138,888	6,473,798,875
	Cost of physicians' sample	(103,474,816)	(44,795,810)
		7,331,664,071	6,429,003,064
	Cost of goods sold for discontinued operations Note-46.4		
		7,331,664,071	6,429,003,064
25.1	**RAW MATERIALS CONSUMED:**		
	This is arrived at as follows :		
	Opening stock	661,133,854	447,551,352
	Purchases	3,935,310,508	3,619,984,401
	Closing stock	-713,243,317	-661,133,854
		3,883,201,045	3,406,401,899
25.2	**PACKING MATERIALS CONSUMED :**		
	This is arrived at as follows :-		
	Opening stock	230,992,875	149,636,336
	Purchases	2,027,904,347	1,814,406,295
	Closing stock	-269,533,870	-230,992,875
		1,989,363,352	1,733,049,756
25.A	**CONSOLIDATED COST OF GOODS SOLD :**		
	This is arrived at as follows:		
	Raw materials consumed Note-25.A.1	4,298,249,495	3,706,324,109
	Packing materials consumed Note-25.A.2	2,183,647,200	1,912,037,354
		6,481,896,695	5,618,361,463
	Opening work-in-process	111,124,876	114,219,828
	Closing work-in-process	-126,653,151	-111,124,876
	Total Consumption	6,466,368,420	5,621,456,415

	Amount	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
Consolidated manufacturing expenses	1,816,597,001	1,541,797,757
Cost of Production	**8,282,965,421**	**7,163,254,172**
Opening finished goods	424,409,351	398,534,726
Closing finished goods	-440,506,971	-424,409,351
	8,266,867,801	**7,137,379,547**
Cost of physicians' sample	(119,783,940)	(53,639,679)
	8,147,083,860	**7,083,739,867**

25.A.1 RAW MATERIALS CONSUMED:

This is arrived at as follows :		
Opening stock	768,094,729	593,235,375
Purchases	4,330,015,617	3,881,183,463
Closing stock	-799,860,851	-768,094,729
	4,298,249,495	**3,706,324,109**

25.A.2 PACKING MATERIALS CONSUMED :

This is arrived at as follows :-		
Opening stock	245,848,438	194,418,191
Purchases	2,233,478,784	1,963,467,601
Closing stock	-295,680,022	-245,848,438
	2,183,647,200	**1,912,037,354**

26. MANUFACTURING EXPENSES :

Particulars		
Salary, wages & allowances	956,042,739	789,665,283
Travelling & Conveyance	6,020,390	2,650,339
Printing & stationery	6,436,141	5,130,886
Repairs & Maintenance-Building	19,796,061	18,487,690
Repairs & Maintenance- Machinery & Equipment	117,609,352	68,989,386
Vehicle fuel & maintenance	12,004,779	11,993,591
Medical expenses	628,727	595,837
Power & Fuel	162,414,467	173,783,005
Training expenses	181,284	414,630
Insurance Premium	9,706,760	9,327,445
Entertainment	2,978,854	3,510,562
Staff Welfare	72,739,639	63,584,087
Telephone, Fax, etc.	2,472,868	2,185,968
Fees & charges	5,185,133	3,322,720
News paper & periodicals	451,349	223,460
Staff Uniform	11,726,477	9,225,004
Laboratory chemicals & stores	24,249,762	18,960,842
Indirect materials	9,596,234	7,151,795
Depreciation	136,007,372	141,189,496
Sundry expenses	116,870	139,120
	1,556,365,257	**1,330,536,247**

(a) The number of employees employed in the factory throughout the year who received aggregate remuneration less than Tk. 36,000 was nil.

(b) The number of employees employed in the factory for part of the year who received aggregate remuneration less than Tk.3,000 per month was nil.

(c) Salary, wages & allowances include P.F. contribution of Tk. 19,605,631 and Gratuity of Tk. 16,338,026.

	Amount	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025

27. ADMINISTRATIVE EXPENSES :

Particulars		
Salary, wages & allowances	142,020,704	124,211,809
Directors' remuneration	12,000,000	11,900,000
Directors' meeting fee	1,811,789	2,423,894
Travelling & conveyance	6,979,792	4,941,025
Repairs & maintenance-building & equipment	15,768,203	15,867,751
Vehicle fuel & maintenance	4,059,224	4,345,861
Audit fees	485,250	350,000
Medical expenses	67,492	53,937
Postage & stamp	182,275	209,859
Training expenses	147,775	241,102
Insurance premium	313,587	465,675
Entertainment	5,830,054	5,642,797
Staff uniform	516,895	251,117
Staff welfare	5,310,085	4,596,166
Telephone, fax, etc.	1,714,559	1,443,247
Fees & charges	6,234,137	4,848,028
Bank Charge	1,283,045	1,794,713
Donation & subscription	34,000	421,000
Advertisement	6,136,577	6,396,030
News paper & periodicals	205,898	236,935
Printing & stationery	2,218,362	2,116,188
Water, electricity & gas	3,994,677	4,173,231
Annual general meeting expenses	2,331,213	1,899,390
Expenses relating to dividend	198,722	78,268
Depreciation	26,910,272	25,635,097
Sundry expenses	10,000	133,500
Expenses relating to CSR	7,068,254	1,000,000
	253,832,840	**225,676,621**

(a) The number of employees employed in the administration department throughout the year who received aggregate remuneration less than Tk. 36,000 was nil.
(b) Salary, wages & allowances include P.F. contribution of Tk. 4,687,500 and Gratuity of Tk. 5,859,450.
(c) The number of employees employed in the administration department for part of the year who received aggregate remuneration less than Tk. 3,000 per month was nil.

27.01 CONSOLIDATED ADMINISTRATIVE EXPENSES :

Particulars		
Salary, wages & allowances	166,941,612	140,429,307
Directors' remuneration	18,370,000	14,250,000
Directors' meeting fee	2,699,825	3,246,619
Travelling & conveyance	11,856,719	5,176,320
Repairs & maintenance-building & equipment	15,956,428	18,795,281
Vehicle fuel & maintenance	4,622,535	4,810,518
Audit fees	738,250	585,750
Medical expenses	67,492	53,937
Postage & stamp	184,974	209,859
Training expenses	255,968	241,102
Insurance premium	3,152,775	2,669,767
Entertainment	5,854,479	5,655,867
Staff uniform	798,330	345,621
Staff welfare	6,809,956	5,358,955
Telephone, fax, etc.	1,918,319	1,452,447
Research & development	2,296,705	940,388
Fees & charges	7,366,961	5,279,943
Bank charge	1,439,776	1,960,027
Donation & subscription	34,000	421,000
Advertisement	6,374,807	6,563,470
News paper & periodicals	205,898	236,935
Printing & stationery	2,496,855	2,375,796
Water, electricity & gas	10,986,917	8,050,069
Annual general meeting expenses	2,331,213	1,899,390
Expenses relating to dividend	198,722	78,268
Depreciation	37,099,769	34,794,768
Sundry expenses	10,000	187,500
Expenses relating to CSR	7,068,254	1,000,000
	318,137,538	**267,068,903**

		Amount	
		01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
28.	**SELLING & DISTRIBUTION EXPENSES :**		
	Particulars		
	Salary, wages & allowances	2,193,592,990	1,855,966,434
	Travelling & conveyance	8,727,247	11,081,320
	Head office & sales centers rent	31,175,344	31,290,466
	Printing & stationery	12,030,431	10,706,931
	Repairs & maintenance-building & equipment	10,417,276	9,006,187
	Vehicle fuel & maintenance	28,092,887	26,204,151
	Medical expenses	2,884,606	1,958,414
	Water, electricity & gas	2,186,163	1,049,113
	Postage & stamp	741,790	705,040
	Field forces conference expenses	25,985,682	22,325,814
	Insurance premium	1,889,665	1,299,039
	Entertainment	3,362,087	2,468,472
	Training expenses	6,968,893	10,309,093
	Staff welfare	2,240,517	-
	Telephone, fax, etc.	12,291,587	12,538,522
	Fees & charges	810,165	677,675
	Advertisement	423,558	97,313
	Incentive	133,262,041	117,239,028
	Sales representatives conference	6,537,061	-
	Detailing bag & brief case	1,382,620	924,850
	Field personnel expenses	501,114,181	455,264,397
	Product development expenses	677,552	521,018
	Product pad & literature	89,922,817	76,210,169
	Promotional expenses	121,188,801	53,096,827
	Physicians' samples	126,188,801	54,629,037
	Market survey & research	8,587,992	7,517,266
	Export expenses	18,726,598	10,142,821
	Delivery expenses	358,983,316	331,123,726
	Depreciation	41,147,797	43,534,036
	Sundry expenses	5,600	17,560
	Staff uniform	121,310	124,953
	Bad debts	2,400,215	1,358,626
		3,754,084,388	**3,149,888,296**
	Less: Expenses for INM	(59,236,595)	(46,305,468)
		3,694,847,793	**3,103,582,828**

(a) The number of employees employed in the selling & distribution department throughout the year who received aggregate remuneration less than Tk. 36,000 was nil.

(b) Salary, wages & allowances include P.F. contribution of Tk. 69,090,936 and Gratuity of Tk. ,,68,860,522.

(c) The number of employees employed in the selling & distribution department for part of the year who received aggregate remuneration less than Tk. 3,000 per month was nil.

	Amount	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025

28.01 CONSOLIDATED SELLING & DISTRIBUTION EXPENSES :

Particulars		
Salary, wages & allowances	2,565,956,073	2,173,998,804
Travelling & conveyance	10,270,624	11,830,353
Head office & sales centers rent	32,354,896	32,432,213
Printing & stationery	12,036,281	10,706,931
Repairs & maintenance-building & equipment	10,418,376	9,012,960
Repairs & maintenance-vehicle & others	28,621,361	26,982,820
Medical expenses	3,699,206	1,969,314
Water, electricity & gas	2,201,909	1,049,113
Postage & stamp	741,790	705,040
Field forces conference expenses	32,340,521	28,062,599
Insurance premium	1,889,665	1,309,558
Entertainment	3,590,360	2,636,665
Training expenses	8,578,132	10,761,670
Staff welfare	2,590,729	285,596
Telephone, fax, etc.	13,082,199	13,552,152
Fees & charges	811,890	689,675
Donation & subscription	19,500	500,000
Advertisement	513,558	159,713
Incentive	141,239,688	124,637,429
Sales representatives conference	6,537,061	-
Detailing bag & brief case	1,666,880	1,171,450
Field personnel expenses	586,468,231	536,035,130
Product development expenses	733,233	753,877
Product pad & literature	91,151,678	77,090,473
Promotional expenses	134,769,064	59,104,961
Physicians' samples	142,497,925	60,579,290
Market survey & research	8,587,992	7,517,266
Export expenses	18,726,598	10,142,821
Delivery expenses	367,868,598	338,069,546
Depreciation	41,905,240	44,004,101
Sundry expenses	13,630	19,797
Staff uniform	121,310	124,953
Bad debts	2,400,215	1,358,626
	4,274,404,411	**3,587,254,894**

(a) Field personnel expense increase due to increase of field personnel movement in order to increase sales.

29. OTHER INCOME:

Dividend income	848,735	103,000
Profit on bank deposits	4,528,055	2,506,832
Foreign exchange fluctuation gain/(Loss) on FCAD ERQ accounts	9,034,412	1,217,618
Toll charge-Income	7,428,448	10,485,573
Export Cash Incentive	8,171,125	-
Rental come from INM and Polymer	610,000	610,000
Received from PF	602,059	304,966
Profit from MTD	2,599,404	4,050,606
Miscellaneous income	1,415,461	2,461,068
	35,237,698	**21,739,663**

i) Toll charge income decreased during the year due to reduction in work order from tall customers.

ii) The amount of provident fund forfeiture has been returned during third period from The IBN SINA Pharmaceutical Industry PLC. Employees provident fund and also recognized as other income as per circular of Financial Reporting Council, Bangladesh no:179/FRC/FRM/Circular/2020/2 dated July 07, 2020.

29.01 CONSOLIDATED OTHER INCOME:

Dividend income	848,735	103,000
Profit on bank deposits	4,608,549	2,972,217
Foreign exchange fluctuation gain/(Loss) on FCAD ERQ accounts	9,034,412	1,217,618
Toll charge-Income	7,428,448	10,485,573
Export Cash Incentive	8,171,125	-
Received from PF	602,059	304,966
Profit from MTD	2,599,404	7,661,581
Miscellaneous income	1,939,510	2,461,068
	35,232,241	**25,206,023**

30. WORKERS' P.P FUND & WELFARE FUND :	**49,806,420**	**42,953,850**

This represents 5% of net profit before tax after charging the contribution as per provision of the Bangladesh Labour Act, 2006 and is payable to workers as defined in the said Act.

		Amount	
		01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
30.1	**CONSOLIDATED WORKERS' P.P FUND & WELFARE FUND :**		
	The IBN SINA Pharmaceutical Industry PLC	49,806,420	42,953,850
	The IBN SINA Natural Medicine Ltd.	3,173,484	404,541
		52,979,904	**43,358,391**
31.	**INCOME TAX EXPENSES:**		
	Current Tax	206,654,091	202,718,520
	Deferred Tax (income)/expense (Note-19)	(3,212,483)	(3,803,551)
	Prior year tax assessment adjustment	-	-
		203,441,607	**198,914,969**
	Tax expenses in relation to Continuing operation	203,522,051	198,914,969
	Tax expenses in relation to discontinuing operation	-	-
		203,522,051	**198,914,969**

31.1 Reconciliation of Effective Tax Rate:

	2025-2026			2024-2025	
Types of income	**Income**	**Effective Tax Rate**	**Tax expenses**	**Tax expenses**	**Rate**
Capital gain	-	20.00%	-	-	15.00%
Dividend income	848,735	20.00%	169,747	20,600	20.00%
Income from associates	-	0.00%		-	0.00%
Business income	995,279,670	20.00%	199,055,934	171,794,799	20.00%
	996,128,405	**20.00%**	**199,225,681**	**171,815,399**	20.03%
Non deductible expenses		0.43%	4,254,241	6,827,610	1.96%
The effect of changes of effective tax rate on opening temporary difference		0.03%	271,726	271,961	-1.14%
Prudency adjustment			-	20,000,000	-
Under estimation in prior year		0.00%	-	-	3.71%
		20.45%	**203,751,648**	**198,914,970**	**24.07%**

31.02	**CONSOLIDATED INCOME TAX EXPENSES:**		
	Current Tax	224,524,099	210,665,371
	Deferred Tax (income)/expense	(2,870,662)	(3,947,246)
	Prior year tax assessment adjustment	-	-
		221,653,436	**206,718,125**
32.	**CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES:**		
	Closing value of marketable securities	(22,790,788)	(17,271,479)
	Opening value of marketable securities	(17,271,479)	(9,567,467)
		(5,519,309)	**(7,704,012)**
33.	**EARNINGS PER SHARE (EPS) :**		
	Basic earnings per share has been calculated as follows :	**2025- 2026**	**2024- 2025**
	Earnings attributable to the Ordinary Shareholders (Net profit after tax)	792,686,798	660,162,024
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
	EARNINGS PER SHARE(EPS)	**25.37**	**21.13**

Earning Per Share (EPS) increased during the year 2025-2026 due to increase in sales and maintaining stable expenses growth.

33.01.A	**CONSOLIDATED EARNINGS PER SHARE (EPS) :**		
	Basic earnings per share has been calculated as follows :		
	Earnings attributable to the owners of the company	794,633,174	633,189,350
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
	EARNINGS PER SHARE(EPS)	**25.43**	**20.27**
33.01.	**Net Assets Value Per Share (NAV):**		
	Net Assets Value	4,520,143,263	3,932,383,056
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
	Net Assets Value Ratio	**144.67**	**125.86**

Net Assets Value Per Share (NAV) increased during the year 2025-2026 due to increase in sales, maintaining stable expenses growth and increase in retained earning.

33.01.B	**Consolidated Net Assets Value Per Share (NAV):**		
	Net Assets Value	4,655,848,970	3,997,848,260
	Less: Non-Controlling Interest	(139,240,723)	(70,946,596)
	Equity Attributable to the owners of the company	4,516,608,247	3,926,901,664
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
	Net Assets Value Per Share	**144.56**	**125.69**

		Amount	
		01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
33.02.	**Net Operating Cash Flow Per Share (NOCFPS):**		
	Net cash provided by operating activities	1,176,592,329	711,823,401
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
		37.66	22.78

Increase in NOCFPS arise due to increase in sales collection and decrease of supplier payment and others and changes in current assets and liabilities.

33.02.01	**Consolidated Net Operating Cash Flow Per Share (NOCFPS):**		
	Net cash provided by operating activities	1,185,621,432	723,678,635
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
		37.95	23.16
33.03.	**Reconciliation of net profit with cash flows from operating activities:**		
	Profit before tax (PBT)	996,128,405	859,076,993
	Adjustment		
	Depreciation	204,065,440	210,358,629
	Deferred Tax	(3,764,414)	(4,573,952)
	Unrealized foreign exchange loss	9,034,412	1,217,618
	Dividend received	(848,735)	(103,000)
	Interest Income	(4,528,055)	(2,506,832)
	Change In operating assets		
	Increase in inventory	(135,019,577)	(264,997,476)
	Increase in accounts receivables	7,351,133	(20,287,478)
	Decrease in advances, deposits and prepayments	(129,086,310)	(37,775,097)
	Increase/(decrease) in trade and other payable	552,191,495	229,829,819
	Increase/(decrease) in retirement benefit obligation	(482,826)	(194,634)
	Tax paid during the year	(190,610,415)	(174,510,320)
	Interest expense	(127,838,224)	(83,710,869)
	Net Cash generated operating activities	1,176,592,329	711,823,401
33.03.A.	**Consolidated Reconciliation of net profit with cash flows from operating activities:**		
	Profit before tax (PBT)	**1,014,580,738**	**839,974,353**
	Adjustment		
	Depreciation	204,065,440	210,358,629
	Deferred Tax	(3,764,414)	(4,573,952)
	Unrealized foreign exchange loss	9,034,412	1,217,618
	Dividend received	(848,735)	(103,000)
	Interest Income	(4,528,055)	(2,506,832)
	Change In operating assets		
	Increase in inventory	(164,295,832)	(222,736,169)
	Increase in accounts receivables	7,351,133	(20,287,478)
	Decrease in advances, deposits and prepayments	(111,250,689)	(47,270,578)
	Increase/(decrease) in trade and other payable	569,587,199	234,178,513
	Increase/(decrease) in retirement benefit obligation	(482,826)	(194,634)
	Tax paid during the year	(205,988,714)	(180,666,965)
	Interest expense	(127,838,224)	(83,710,869)
	Net Cash generated operating activities	1,185,621,432	723,678,635
33.04.	**FINANCE CHARGE:**		
	Finance charge for long term finance.	126,555,744	83,710,869
	Finance charge for lease	1,282,480	3,692,459
		127,838,224	87,403,328

Finance charge increased due to increased in long term loan.

33.04.1	**CONSOLIDATED FINANCE CHARGE:**	126,555,744	83,710,869
	Finance charge for long term finance.	1,282,480	3,692,459
	Finance charge for lease	127,838,224	87,403,328

33.05.	**NON-CONTROLLING INTEREST**	**Profit Amount**	**(%)**	**Net Amount**
	The IBN SINA API Industry Ltd.	(40,087,406)	0.000067	(27)
	The IBN SINA Natural Medicine Ltd.	45,976,099	0.001260	579
	The IBN SINA Polymer Industry Ltd.	(4,875,501)	35.000000	(1,706,425)
		1,013,192		(1,705,873)

34. VALUE OF IMPORTS ON CIF BASIS:

	Amount in Taka	
	30 June 2026	30 June 2025
Materials (raw & packing)	3,148,198	2,998,284
Components & spare parts	10,297	9,807
Capital goods	131,612	125,345
	3,290,108	**3,133,436**

34.1 Value of import and local purchase:

Value of import and local purchase Raw materials consist of 9805 items which 95.69% are imported.

Value of import and local purchase Packing materials consist of 3,290 items which 4.31% are imported.

35. INSTALLED CAPACITY, ACTUAL PRODUCTION ON SINGLE SHIFT BASIS AND REASONS FOR SHORT-FALL DURING THE YEAR ENDED 30th June, 2026 :

Quantity in Thousand

		2025-2026		2024-2025	
Product group	Unit	Installed	Actual Production	Installed	Actual Production
Tablet	Pcs	1,223,000	1,319,116	1,223,000	1,304,926
Capsule	Pcs	410,000	480,801	410,000	418,324
Dry Syrup / ORS	Bottle	57,773	28,218	57,773	31,377
Liquid	Bottle	37,000	36,022	37,000	32,077
Drops	Pcs	6,124	7,607	6,124	7,745
Ointment	Pcs	16,555	10,578	16,555	9,042
Injection	Pcs	19,154	10,745	18,798	8,733

Production was made keeping in view market demand.

36. RELATED PARTY TRANSACTIONS:

During the year, the company carried out transactions with related parties in the normal course of business and on an arm's length basis. The name of related parties, relationship, types of transaction and their total value have been set out in accordance with the provisions of IAS 24 "Related Party Disclosures". Transaction with related parties are executed on the same terms as those of other customers of similar credentials and do not involve more than a normal risk.

Name of party	Relationship	Nature of transaction	Transaction		30-Jun-26
			Dr.	Cr.	Receivable/(Paya
1.The IBN SINA Trust	Sponsor shareholder	Dividend payment	88,597,197	-	-
2. The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		130,000,000	799,999,800
		Receivable	-		-
3. The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Capital	-	-	238,169,670
		Lease rental		250,000	
		Distribution commission		59,236,595	
		Receivable/Payable	-	-	
4. IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Acquisition of share Capital		70,000,000	
		Lease rental		270,000	

i) The company has been allotted a pieces of land (1.52 Akor) by BSCIC in API Park,(Gozaria, Munshigonj). The company has transferred the right of said land to its 99.99% owned Subsidiary named: The IBN SINA API Industry Ltd. at cost.

ii) Related party transactions between the company and its subsidiaries have been eliminated in the consolidation

36.1 Key management benefit disclosure personnel and their compensation :

Particulars		2025-2026	2024-2025
Short term employee benefits	No. of Director-4	12,000,000	11,900,000
Post-employment benefits		-	-
Other long term benefits		-	-

Key management personnel compensation includes benefits for employees of the rank of director and above. No remuneration is given to the board of director's apart from attendance fees in connection with board and sub committee meeting during the year 2025-2026. Attendance fees in connection with board and sub board committee meeting are Tk. 1,811,789 (2025-2026 Tk.2,423,894).

Debts due from and due to key management personnel.
There is no debts due from and due to key management personnel of the company.

37. Commitment and contingency. There was no contract for Capital Expenditure remaining to be executed and not provided for at 30 June 2026.

38. There was no general nature of credit facilities available to the company under any contract other than trade credit available in the ordinary course of business and not availed of as on 30.06.2026.

39. No brokerage or discount other than usual trade discount against sales was paid during the year.

40. As there was no sales agent, commission therefore was not paid.

41. There is no regular employees who received remuneration less than 36,000.00 in aggregate throughout the financial year.

42. As there was no non-resident shareholder, no dividend was remitted abroad.

43. At the end of this year closing balance of FCAD ERQ account was USD $11,95,199.54 out of which USD $90,498.49 in IBBL, USD $11,01,766.28 in AIBL and USD $ 2,934.77 in Sonali Bank PLC.

44. There were aggregating income tax claims of Tk. 11,047,567 in respect of assessment years 2012-2013, 2013-2014 and 2014-2015 respectively against the Company for Income Tax in different years but no asset or liability was recognized for the claims. The Company filed Income Tax Reference case with High Court Division of the Supreme Court & Appeals remained pending for adjustment for these cases.

45. There was no contingent liability other than letters of credit outstanding for importation of raw & packing materials, capital goods as on 30.06.2026.

46. FINANCIAL RISK MANAGEMENT:

The company management has overall responsibility for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risks from its use of financial instruments.

(a) Credit Risk
(b) Liquidity Risk
(c) Market Risk

46.1 Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the company's receivables. Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. As at 30th June 2026, substantial part of the receivables are as follows and subject to insignificant credit risk. Risk exposures from other financial assets, i.e. Cash at bank and other external receivables are also nominal.

(i) Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting data was:

	Amount in Taka	
	30 June 2026	30 June 2025
Accounts receivable:		
Advance to employees	6,102,581	5,482,341
Advance to suppliers	12,433,414	12,433,414
Trade receivable (net of bad dept provision)	170,988,026	181,402,168
Other receivables	77,086,030	52,075,437
Security deposit	20,580,535	21,275,544
Imprest cash	3,535,000	3,540,000
Cash at bank	149,773,374	170,528,294
	440,498,960	**446,737,199**

The aging of trade receivables at the reporting date is as follows:

Trade receivables (gross)		
Below 30 days	117,240,051	124,764,508
With in 61-90 days	43,485,156	45,591,093
With in 91-120 days	2,846,581	7,011,122
Above 180 days	9,816,453	5,394,071
	173,388,241	**182,760,794**

i) To mitigate the credit risk against trade receivables, the company has a system of specific credit line period to the customers. This outstanding period and amount are regularly monitored. The company endeavors to cover the credit risks on all other receivables, where possible, by restricting credit facility and stringent monitoring.

ii) All of the company's advance, trade receivable are considered good. All of the receivable are considered collectable and hence no doubtful or bad receivable included under trade receivable.

iii) The company did not make any advance, deposit, prepayment to the director, subsidiary, associates or other connected party and advance employees are realized in normal course of business.

iv) Security deposit include advance Tk. 11,661,000 given for head office rent which is adjustable at end of rent

Consolidated Accounts receivable:		
Advance to employees	16,459,616	9,555,942
Advance to suppliers	13,573,966	31,119,648
Trade receivable (net of bad dept provision)	170,988,026	181,402,168
Other receivables	91,201,628	72,758,441
Security deposit	21,635,232	22,330,241
Imprest cash	3,665,000	3,670,000
Cash at bank	285,023,263	304,095,694
	602,546,730	**624,932,134**

The aging of trade receivables at the reporting date is as follows:

Trade receivables (gross)		
Below 30 days	117,240,051	124,764,508
With in 61-90 days	43,485,156	45,591,093
With in 91-120 days	2,846,581	7,011,122
Above 180 days	9,816,453	5,394,071
	173,388,241	**182,760,794**

46.2 Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalents to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. The carrying amount of financial liabilities represent the maximum exposure to liquidity risk. The maximum exposure to liquidity risk as at 30th June was:

Trade and other Payables	705,359,343	354,248,263
Security money received from employees	12,437,585	11,517,972
Other current liabilities	49,806,420	42,953,850
	767,603,349	**408,720,085**

46.3 Market Risk

Market risk is the risk that any change in market prices, such as foreign exchange rates and interest rates will affect the company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(i) Interest Rate Risk

Interest rate risk is the risk that fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate. Exposure to fair value movement relates to fixed rate instrument subject to fair value accounting and exposure to cash flow fluctuation relates to variable rate instruments. The Company is primarily exposed to cash flow fluctuation arising from variable rate borrowings. The objective of interest rate management for The IBN SINA Pharmaceutical Industry PLC is to reduce financial cost and ensure predictability.

(ii) Currency risk

The company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw material, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD and related to procurement of raw materials, machineries and equipment from abroad.

47. EVENTS AFTER THE REPORTING PERIOD :

The Board of Directors of the company approved the financial statements as on 30/09/2026 and recommended 77% cash dividend for the financial year ended June 30, 2026.

PROPERTY, PLANT AND EQUIPMENT: (PPE)
AS AT 30th JUNE, 2026

Annexure-A
Amount in Taka

Particulars	Cost/ Revaluation					Depreciation				Written down value on 30.06.2026
	On 01.07.2025	Addition during the year	Disposal / Adjustment	Total on 30.06.2026	Rate	On 01.07.2025	For the year	Disposal / Adjustment	Total on 30.06.2026	
Land & Land Development	599,267,406	-	-	599,267,406	-	-	-		-	599,267,406
Building	380,819,686	-		380,819,686	2.50%	69,022,448	7,794,931		76,817,379	304,002,307
Plant & Machinery	1,779,206,037	42,161,490		1,821,367,526	10.00%	983,734,122	80,386,613		1,064,120,735	757,246,791
Internal Road	4,842,880	-	-	4,842,880	10.00%	3,738,858	110,402		3,849,260	993,620
Installations	93,924,272	-	-	93,924,272	10.00%	45,283,773	4,864,050		50,147,823	43,776,449
Equipment	812,151,720	59,510,819		871,662,540	10.00%	300,953,051	52,210,424		353,163,474	518,499,065
Computers	72,371,404	6,546,079		78,917,483	30.00%	56,060,961	5,797,728		61,858,690	17,058,793
Furniture & Fixtures	91,965,922	15,107,560		107,073,482	10.00%	48,518,324	5,015,788		53,534,112	53,539,370
Motor Vehicles	253,209,246	7,765,831	-	260,975,077	20.00%	186,083,689	14,183,031	-	200,266,720	60,708,358
Motorcycle	43,945,025	6,132,425		50,077,450	20.00%	8,789,005.00	8,257,689		17,046,694	33,030,756
Spares & Loose Tools	28,009,108	-		28,009,108	30.00%	26,189,868	545,772		26,735,640	1,273,468
Library Books	867,659	-		867,659	30.00%	848,906	5,626		854,532	13,127
Temporary Construction	8,489,054	-		8,489,054	30.00%	8,192,876	88,853		8,281,730	207,324
TOTAL-30th June, 2026	**4,169,069,419**	**137,224,204**	**-**	**4,306,293,623**		**1,737,415,883**	**179,260,907**	**-**	**1,916,676,789**	**2,389,616,834**
TOTAL-30th June, 2025	**3,956,915,644**	**215,232,652**	**(3,078,877)**	**4,169,069,419**		**1,554,782,910**	**185,554,095**	**(2,921,123)**	**1,737,415,882**	**2,431,653,537**

Allocation of depreciation:

Allocation to	Note no.	Allocated Depreciation 2025-2026			Allocated Depreciation 2024-2025		
		PPE	ROU	Total	PPE	ROU	TOTAL
Manufacturing Expenses	Note-26	136,007,372	-	136,007,372	141,189,496	-	141,189,496
Administrative Expenses	Note-27	17,102,518	9,807,753	26,910,272	16,442,173	9,192,925	25,635,098
Selling & Distribution Expenses	Note-28	26,151,017	14,996,780	41,147,797	27,922,427	15,611,609	43,534,036
Total		**179,260,907**	**24,804,533**	**204,065,440**	**185,554,095**	**24,804,534**	**210,358,629**

The company has been allotted a pieces of land (152 Decimel) by BSCIC in API Park,(Gozaria, Munshigonj). The company is transferred the right of said land to its 99.99% owned subsidiary named: IBN SINA API Ltd. at cost.

CHARTERED ACCOUNTANTS

Investment of Marketable Securities (Fair Value): 2025-2026

Annexure-B

SL. No	Name of Company Mutual Fund/Bond	No. of Shares Held	Face Value per Share	Cost Holding	Average Cost	Quoted Rate per Share as on 30-06-2026	Total Market Value of Shares as on 30-06.2026	Unrealised Gain/(Loss)
1	Exim Bank PLC	380,000	10.00	4,461,895	11.74	3.00	1,140,000	(3,321,895)
2	First Security Islami Bank PLC	2,051,000	10.00	19,129,655	9.33	1.90	3,896,900	(15,232,755)
3	Shahjalal Islami Bank PLC	103,000	10.00	2,096,388	20.35	18.00	1,854,000	(242,388)
4	Al-Arafah Islami Bank PLC	108,150	10.00	2,633,035	24.35	15.50	1,676,325	(956,710)
5	Social Islami Bank PLC	173,643	10.00	2,159,166	12.43	3.00	520,929	(1,638,237)
6	Islami Bank Bangladesh PLC)-in Mddaraba Perpetual Bond (MPB)	4,590	1,000.00	4,448,858	969.25	664.50	3,050,055	(1,398,803)
	Total	**2,820,383**		**34,928,997**			**12,138,209**	**(22,790,788)**

The above Investment in Marketable Securities that are designated as available for sale by the management. These are measured at fair value and presented as non-current asset and unrealized gain/(loss) from the above investment are recognized as other comprehensive income.

Amount in Taka

	July 01, 2025 to June 30, 2026	July 01, 2024 to June 30, 2025
Gain/(Loss) On Marketable Securities (Unrealized):		
Unrealised Gain/(Loss) Position (Closing)	(22,790,788)	(17,271,479)
Unrealised Gain/(Loss) Position (Opening)	(17,271,479)	17,657,518
Gain on marketable securities during the year	(5,519,309)	(34,928,997)

04 Investment of Marketable Securities (Fair Value): 2024-2025

SL. No	Exim Bank	No. of Shares Held	Face Value per Share	Cost Holding	Average Cost	Quoted Rate per Share as on 30-06-2025	Total Market Value of Shares as on 30-06.2025	Unrealised Gain/(Loss)
1	Exim Bank PLC	380,000	10.00	4,461,895	11.74	5.50	2,090,000	(2,371,895)
2	First Security Islami Bank PLC	2,051,000	10.00	19,129,655	9.33	3.80	7,793,800	(11,335,855)
3	Shahjalal Islami Bank PLC	103,000	10.00	2,096,388	20.35	16.50	1,699,500	(396,888)
4	Al-Arafah Islami Bank PLC	108,150	10.00	2,633,035	24.35	17.10	1,849,365	(783,670)
5	Social Islami Bank PLC	173,643	10.00	2,159,166	12.43	7.40	1,284,958	(874,208)
6	Islami Bank Bangladesh PLC)-in Mddaraba Perpetual Bond (MPB)	4,590	1,000.00	4,448,858	969.25	640.50	2,939,895	(1,508,963)
	Total	**2,820,383**		**34,928,997**			**17,657,518**	**(17,271,479)**

The above Investment in Marketable Securities that are designated as available for sale by the management. These are measured at fair value and presented as non-current asset and unrealized gain/(loss) from the above investment are recognized as other comprehensive income.

	July 01, 2024 to June 30, 2025	July 01, 2023 to June 30, 2024
Gain/(Loss) On Marketable Securities (Unrealized):		
Unrealized Gain/(Loss) Position (Closing)	(17,271,479)	17,657,518
Unrealized Gain/(Loss) Position (Opening)	17,657,518	34,928,997
Gain on Marketable Securities during the year	(34,928,997)	(17,271,479)

BANGLADESH ASSOCIATION OF PUBLICLY LISTED COMPANIES

Renewed Certificate

This is to certify that

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

is an Ordinary Member of Bangladesh Association of Publicly Listed Companies and is entitled to all the rights and privileges appertaining thereto.

This certificate remains current until 31st December, **2026**

Ref. No: **CM-2026/174**

Date of issue : **April 8, 2026**

BAPLC

Secretary General